Journal of Endocrine Disorders

Open Access

Austin Publishing Group

Review Article

Pharmacological Modulation of the Gut Microbiome in Metabolic Disorders

Neha Fatima[1] and Md Ejaz Alam[2]*

[1]Department of Pharmacology, Patna Medical College, Patna, India

[2]Department of Endocrinology, Government Medical College, Srinagar, India

***Corresponding author:** Md Ejaz Alam, Department of Endocrinology, Government Medical College, Srinagar, India

Email: ejaz2k6@gmail.com

Received: September 09, 2025

Accepted: September 18, 2025

Published: September 23, 2025

Abstract

The gut microbiome, a complex ecosystem influencing host metabolism, immunity, and inflammation, has emerged as a pivotal regulator in the pathogenesis and treatment of metabolic disorders, including obesity, type 2 diabetes mellitus (T2DM), metabolic-associated steatotic liver disease (MASLD), and insulin resistance. Dysbiosis—characterized by reduced microbial diversity and shifts toward pro-inflammatory taxa—contributes to metabolic dysfunction through altered short-chain fatty acid (SCFA) production, impaired gut barrier integrity, systemic endotoxemia, and disrupted bile acid signaling. Pharmacological modulation of the gut microbiome offers a novel therapeutic paradigm, with agents such as metformin, dipeptidyl peptidase-4 inhibitors, berberine, and bile acid pathway modulators demonstrating microbiota-mediated metabolic benefits in preclinical and clinical studies. Mechanistic pathways include enrichment of beneficial taxa (e.g., Akkermansia muciniphila, Bifidobacterium), restoration of gut barrier function, modulation of bile acid-FXR/TGR5 signaling, and regulation of microbial metabolite-driven host pathways. Advanced strategies—such as engineered microbial consortia, next-generation probiotics, and microbiome-derived metabolites—promise precision-targeted interventions, particularly when integrated with dietary and lifestyle modifications. Despite promising evidence, translation to clinical practice faces challenges including interindividual microbiome variability, limited long-term safety data, and lack of standardized protocols. Future directions focus on biomarker-guided personalization, multi-omics integration, and large-scale randomized trials to optimize the efficacy, safety, and durability of microbiome-targeted pharmacotherapies for metabolic diseases.

Keywords: Gut microbiome; Microbiota modulation; Metabolic disorders; Type 2 diabetes mellitus; Short-chain fatty acids; Bile acid signaling

Main Points

1. Gut Microbiome in Metabolic Health – Dysbiosis (loss of microbial diversity, depletion of beneficial bacteria like Akkermansia and Bifidobacterium) contributes to obesity, T2DM, insulin resistance, and MASLD via impaired SCFA production, gut barrier dysfunction, endotoxemia, and altered bile acid signalling.

2. Pharmacological Modulation – Drugs like metformin, DPP-4 inhibitors, and berberine exert part of their benefits by reshaping the gut microbiome, enriching beneficial taxa, improving gut integrity, enhancing SCFA production, and modulating bile acid–FXR/TGR5 pathways.

3. Emerging Therapies – Novel strategies include engineered microbial consortia, next-generation probiotics (e.g., Akkermansia muciniphila), and microbiome-derived metabolites to achieve precision-targeted interventions.

4. Clinical Evidence & Challenges – While rodent models and small human trials show promise, translation to clinical practice is limited by interindividual variability, lack of standardized protocols, and insufficient long-term safety data.

5. Future Directions – Integration of dietary/lifestyle interventions, biomarker-guided personalization, and multi-omics approaches with pharmacological microbiome modulation holds potential for sustainable management of metabolic diseases.

Introduction

The human gut microbiome is a vast and diverse ecosystem composed of trillions of microorganisms, including bacteria, archaea, fungi, protists, and viruses, residing primarily in the gastrointestinal tract. Characterized by immense compositional diversity, the microbial community exhibits variability across different individuals, populations, and even within various gastrointestinal niches. This diversity is crucial for maintaining a balanced symbiosis that underpins numerous vital physiological functions. The gut microbiota plays an essential role in nutrient metabolism by fermenting indigestible dietary components such as fibers into beneficial metabolites like short-chain fatty acids (SCFAs), which can modulate host energy homeostasis and immune responses. It also influences the integrity of the gut barrier, shaping mucosal immunity and systemic immune tolerance. Furthermore, the microbiome contributes to the biosynthesis of vitamins, production of neurotransmitters, and

Citation: Neha Fatima, Md Ejaz Alam. Pharmacological Modulation of the Gut Microbiome in Metabolic Disorders. J Endocr Disord. 2025; 10(1): 1052.

regulation of inflammatory pathways, thereby exerting systemic effects beyond the confines of the gut. The interplay between the gut microbiome and the host is integral to maintaining homeostasis, wherein the microbiota functions almost as an "extended genome" of the host organism, influencing health and disease states. Alterations to this microbial community, a state termed dysbiosis, are increasingly implicated in the pathophysiology of both local and systemic disorders. Advanced systems biology and multi-omics approaches have revealed mechanistic insights into how microbial metabolites and genetic functionalities influence host metabolic pathways, immune modulation, and neuroendocrine communication. Consequently, the gut microbiome is recognized as a dynamic regulator of health, with implications spanning metabolic, cardiovascular, neurological, and gastrointestinal diseases [1]. Comprehensive reviews emphasize the pivotal functions of gut microbiota in modulating energy metabolism and systemic inflammation, which are key drivers in chronic metabolic diseases [2]. The potential for harnessing microbiome-targeted approaches to prevent or mitigate such diseases continues to stimulate intensive research [3].

Metabolic Disorders and their Association with Gut Dysbiosis

Metabolic disorders encompass a constellation of interconnected pathophysiological states, collectively termed metabolic syndrome (MetS). This syndrome includes obesity, insulin resistance, type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, and nonalcoholic fatty liver disease. Central to these conditions is the dysregulation of metabolic homeostasis, often intertwined with chronic low-grade inflammation and altered energy balance. Emerging evidence has positioned gut microbiota dysbiosis as a critical contributor to the onset and progression of metabolic disorders.

Dysbiosis in metabolic diseases is characterized by reductions in bacterial diversity and shifts in microbial composition, including the depletion of beneficial bacteria such as Akkermansia muciniphila and Bifidobacterium species, with a concomitant increase in pro-inflammatory taxa like Proteobacteria. Studies have demonstrated that such alterations may influence host metabolism by affecting pathways related to energy harvest from the diet, lipid metabolism, and glucose homeostasis. Mechanistically, the microbiota contributes to metabolic dysfunction via several pathways: modulation of bile acid metabolism, disruption of the intestinal barrier leading to systemic endotoxemia, and altered production of microbial metabolites such as SCFAs, which have immunomodulatory and metabolic regulatory functions.

The causal role of gut microbiota dysbiosis is underlined by preclinical studies showing that transplantation of microbiota from obese or insulin-resistant donors can transfer disease phenotypes to germ-free animals. Moreover, therapeutic interventions targeting microbiome restoration, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), have yielded improvements in metabolic parameters, underscoring the microbiota's influence [4]. This body of research supports the hypothesis that maintaining microbial homeostasis is crucial for metabolic health and that disturbances in this balance can precipitate or exacerbate metabolic disorders [5]. Reviews further address controversies and open questions regarding whether microbiota alterations are cause or consequence in human metabolic diseases, highlighting the need for more mechanistic and longitudinal studies [6].

Therapeutic Potential of Modulating the Gut Microbiome

Given the significant roles of the gut microbiome in metabolic disorders, there is substantial rationale for targeting the gut microbiota as a therapeutic avenue. Modulation of the microbial community composition and functions offers a novel paradigm to influence metabolic disease outcomes, complementing traditional pharmacological approaches directed at host targets. Strategies include the administration of probiotics (live beneficial microorganisms), prebiotics (substrates that foster growth of beneficial microbes), synbiotics (combinations of probiotics and prebiotics), and advanced methods such as fecal microbiota transplantation (FMT).

Pharmacological agents known to impact metabolic disorders also have microbiome-modulatory effects. For example, drugs like metformin, beyond their systemic metabolic actions, can alter gut microbial composition, potentially mediating part of their therapeutic benefits. Dietary interventions similarly modify gut flora, influencing microbial metabolite production and host metabolism. However, despite the promising potential of microbiome modulation, multiple challenges remain. These include variability in microbiota composition among individuals, limited understanding of causal mechanisms, and the complexity of microbial-host interactions.

Translating preclinical findings into effective human treatments requires overcoming these challenges while establishing safe and efficacious intervention protocols. Moreover, the transient nature of many microbial interventions highlights the need for sustained or combinatorial approaches. Future prospects involve integrating microbiome modulation with personalized medicine, leveraging omics-based biomarker discovery, and refining microbial therapeutics for metabolic diseases [7]. Current reviews call for coordinated efforts across stakeholders to develop live microbial agents, next-generation probiotics, and less resource-intensive delivery methods, emphasizing the need for standardized clinical trials to demonstrate consistent therapeutic benefits [8]. The clinical application of these modalities requires addressing limitations in durability, reproducibility, and mechanistic clarity to realize the full potential of microbiome-targeted therapies [9].

Pharmacological Agents Targeting the Gut Microbiome in Metabolic Disorders

Metformin and Its Effects on Gut Microbiota and Metabolism

Metformin, the first-line pharmacotherapeutic agent for T2DM, epitomizes the emerging concept that commonly used drugs may exert part of their effects via modulation of the gut microbiome. Evidence from metagenomics and animal models demonstrates that metformin induces distinct shifts in gut microbial community structure, notably increasing the relative abundance of beneficial taxa such as Akkermansia muciniphila and species within the Bifidobacterium and Lactobacillus genera. This reconfiguration is associated with improved intestinal barrier integrity, enhanced short-chain fatty acid (SCFA) production, and reduced systemic inflammation.

SCFAs, such as butyrate, propionate, and acetate, produced by fermentative bacteria, have been shown to improve glucose and lipid

metabolism by serving as energy substrates, enhancing gut hormone secretion, and regulating inflammatory responses. Metformin's effects on microbial SCFA producers suggest a mechanism whereby it indirectly reinforces gut metabolic homeostasis. The drug also strengthens gut barrier functions, lowering metabolic endotoxemia caused by lipopolysaccharides (LPS) translocation, which contributes to insulin resistance and chronic inflammation.

Rodent models have provided mechanistic insights into these effects, demonstrating that disruption of the microbiota or depletion of specific bacterial taxa attenuates the drug's hypoglycemic impact. Human studies corroborate these findings, showing that metformin treatment alters the microbiome in T2DM patients, partially restoring dysbiotic profiles toward healthier compositions. Furthermore, clinical observations point toward the gut as a potential therapeutic target of metformin, in addition to its classical hepatic and muscular actions. Together, these findings position metformin as a prototype for pharmacological agents that leverage gut microbiota modulation to achieve metabolic benefits [4,10,11].

Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) and Microbiome Modulation

Dipeptidyl peptidase-4 inhibitors (DPP-4i), another class of anti-diabetic agents, influence the gut microbiota in ways that may contribute to their glucose-lowering effects. Studies in high-fat diet (HFD) fed mice have documented that treatment with DPP-4i, such as sitagliptin and related molecules, can partially reverse HFD-induced microbial dysbiosis. Specifically, DPP-4i enrich the abundance of Bacteroidetes phylum members, which are linked to improved metabolic profiles.

Functional shifts evoked by DPP-4i include heightened production of succinate, a microbial metabolite implicated in glucose homeostasis and energy metabolism. Fecal microbiota transplantation (FMT) experiments transferring microbiota from DPP-4i-treated donors to germ-free mice reproduced enhanced glucose tolerance, whereas FMT from placebo-treated donors did not, underscoring a causal role for microbiome alterations in mediating DPP-4i benefits.

These data suggest that DPP-4i pharmacodynamics encompass microbiome-mediated mechanisms, involving changes not only in community composition but also in metabolic capacity. The understanding of these contributions may facilitate the development of targeted microbial therapies augmenting or mimicking DPP-4i effects, and support the use of microbiota biomarkers for therapeutic response monitoring [11,12].

Other Pharmacological Agents: Berberine, Sirolimus, and Novel Drugs

Berberine, a plant-derived isoquinoline alkaloid, possesses anti-obesity and anti-diabetic properties linked partly to microbiota modulation. It enhances the abundance of probiotic taxa such as Akkermansia muciniphila and Bifidobacterium, promoting SCFA production and improving gut barrier integrity. These microbial changes contribute to attenuated systemic inflammation and metabolic endotoxemia, translating to improved insulin sensitivity and lipid metabolism in preclinical models. Sirolimus, an immunosuppressive agent used post-transplantation, has been associated with adverse metabolic effects, including dyslipidemia and glucose intolerance. Recent murine studies reveal that sirolimus induces intestinal dysbiosis characterized by Proteobacteria enrichment and Akkermansia depletion. These alterations are accompanied by compromised gut barrier function and elevated circulating pro-inflammatory cytokines, thereby linking microbiome disruption to sirolimus-induced metabolic disorders. Notably, intervention with Lactobacillus rhamnosus HN001 attenuates dysbiosis and systemic inflammation, illustrating the therapeutic potential of microbiota-targeted strategies to mitigate drug-induced metabolic side effects.

Emerging pharmacological agents targeting bile acid pathways and microbial metabolites hold promise in metabolic disorder management. Modulating bile acid synthesis, transformation, and signaling via gut microbes can influence host metabolism through receptors such as farnesoid X receptor (FXR) and TGR5, and contribute to improved metabolic homeostasis[4,13,14].

Mechanisms of Gut Microbiome Modulation by Pharmacological Interventions

Enhancement of Beneficial Bacterial Taxa and SCFA Production

A key mechanism by which pharmacological agents modulate host metabolism involves the promotion of beneficial bacterial taxa such as Akkermansia muciniphila, Bifidobacterium, and Lactobacillus. These microbes ferment dietary fibers into SCFAs, which have well-documented effects on host energy metabolism, gut barrier function, and immune regulation. SCFAs activate G-protein coupled receptors on enteroendocrine and immune cells, promote secretion of satiety hormones (e.g., GLP-1, PYY), and mitigate inflammatory signaling. Pharmacological interventions, including metformin and berberine, selectively enrich these SCFA-producing microbes, leading to improved metabolic profiles. The outer membrane protein Amuc_1100 from Akkermansia muciniphila has been implicated in modulating host immune responses and enhancing gut barrier integrity. Moreover, the abundance of SCFA-producers correlates inversely with obesity, insulin resistance, and systemic inflammation. The sustained elevation of such microbial populations contributes to the restoration of intestinal homeostasis and attenuation of metabolic endotoxemia. These mechanisms have been corroborated in various animal models, and changes in microbial taxa and SCFA levels often parallel improvements in glucose and lipid metabolism [4,15,16].

Restoration of Gut Barrier Integrity and Reduction of Endotoxemia

Disruption of the intestinal barrier is a hallmark of metabolic disorders, leading to increased permeability ("leaky gut") and systemic exposure to bacterial endotoxins, particularly lipopolysaccharides (LPS). This promotes chronic low-grade inflammation, insulin resistance, and metabolic dysfunction. Pharmacological agents modulating the gut microbiome can restore barrier integrity by enhancing tight junction protein expression and mucosal layer thickness.

For instance, sirolimus has been shown to reduce mucosal thickness and increase permeability, exacerbating systemic inflammation. Interventions with probiotic strains like Lactobacillus

rhamnosus HN001 counteract these effects by depleting LPS-producing bacteria and normalizing barrier function. Similarly, metformin-induced microbial shifts improve gut barrier dynamics, contributing to reduced endotoxemia. These effects underscore microbiome modulation as a therapeutic target to diminish systemic inflammation driven by microbial translocation. Attenuation of endotoxin-driven Toll-like receptor activation reduces inflammatory cascades, improving insulin signaling and alleviating metabolic symptoms [4,9,13].

Modulation of Bile Acid Metabolism and Signaling Cascades

The gut microbiota plays an essential role in bile acid metabolism by transforming primary bile acids synthesized in the liver into secondary bile acids via deconjugation and dehydroxylation reactions. Bile acids serve as signaling molecules, interacting with nuclear and membrane receptors such as the farnesoid X receptor (FXR) and the Takeda G-protein-coupled receptor 5 (TGR5). These interactions regulate glucose, lipid metabolism, energy expenditure, and inflammation.

Pharmacological agents can influence the composition of microbial communities responsible for bile acid transformations, thereby reshaping the bile acid pool and its signaling effects. For example, modifications in taurine-conjugated bile acid species post-gastric bypass surgery have been linked to improved metabolic outcomes through enhanced FXR and TGR5 signaling, promoting adaptive thermogenesis and glycemic control. Gut microbiota-driven modulation of bile acid receptors offers a promising therapeutic axis to correct metabolic dysfunctions, with potential for novel drugs targeting the microbiome-bile acid interface to ameliorate glucose and lipid disorders [9,14,17].

Clinical and Preclinical Evidence Supporting Microbiome-Targeted Pharmacotherapy

Rodent Models Demonstrating Pharmacological Effects on Microbiota and Metabolism

Preclinical rodent models, particularly high-fat diet (HFD) induced obesity and metabolic syndrome models, have been instrumental in elucidating microbiome-mediated mechanisms of pharmacological agents. Metformin and berberine treatment in HFD-fed rodents consistently demonstrate enrichment of probiotic bacterial taxa, increased SCFA production, and improved metabolic markers such as insulin sensitivity and lipid profiles.

Sirolimus administration in mice has been shown to induce dose-dependent metabolic disturbances accompanied by marked dysbiosis, characterized by the proliferation of Proteobacteria and loss of key beneficial bacteria. Interventions restoring Lactobacillus populations mitigated these adverse metabolic effects, emphasizing the link between microbiota remodeling and drug-induced metabolic outcomes. Additionally, germ-free and recolonization studies have highlighted the critical role of the gut microbiota in regulating host lipid metabolism, energy balance, and xenobiotic metabolism, confirming the multifaceted influence of microbial communities on pharmacological responses [4,13,18].

Human Clinical Trials and Observational Studies

In clinical contexts, probiotics and fecal microbiota transplantation (FMT) have emerged as potential adjuncts in managing metabolic syndrome, albeit with challenges in reproducibility and heterogeneity of outcomes. While FMT has demonstrated proof-of-concept for microbiome modulation to improve insulin sensitivity and metabolic markers, its resource-intensive nature and procedural risks limit widespread application. Probiotic supplementation with specific strains such as Lactobacillus reuteri DSM 17938 and Bifidobacterium bifidum has yielded modest clinical benefits in gastrointestinal and metabolic parameters. However, the variability in host microbiota, dosage, and treatment duration complicates outcome consistency. Metformin and DPP-4i treatments in humans have been associated with shifts in gut microbial composition, paralleling preclinical findings and supporting microbiota involvement in drug efficacy. Nonetheless, large-scale randomized controlled trials with standardized protocols remain necessary to validate these therapeutic strategies and optimize clinical utility [8,19,20].

Limitations of Current Models and Translational Challenges

The translational leap from preclinical models to human applications is complicated by several limitations. Species-specific differences in microbiota composition and function pose challenges in extrapolating rodent data. The short duration of many animal studies limits understanding of long-term microbiome and metabolic adaptations.

Interindividual variability in human microbiome composition and host genetics further complicate treatment response predictability. These factors underscore the need for long-term, large-scale, personalized studies to delineate effective microbiome-mediated therapies and identify biomarkers predictive of therapeutic success. Additionally, the dynamic and context-dependent nature of the gut microbiome requires multipronged approaches integrating diet, lifestyle, and pharmacological agents tailored to individual microbiota profiles for sustained metabolic benefits [4,8,9].

Advanced Therapeutic Strategies and Next-Generation Probiotics

Engineered Microbial Consortia for Precision Modulation

A frontier in gut microbiome modulation involves engineering artificial microbial consortia—carefully designed and synthetically constructed communities of microorganisms tailored to perform specific functional roles in the gut ecosystem. Drawing on advances in synthetic biology and systems biology, these consortia can be customized to enhance therapeutic molecule production, modulate immune responses, and inhibit pathogenic bacteria through ecological competition.

Preclinical studies indicate that such engineered consortia can effectively restore microbial balance and improve host resilience against metabolic and inflammatory disorders. Personalized consortia allow precise targeting of individual microbiome aberrancies, offering a transformative approach beyond conventional probiotics and FMT. The field awaits rigorous clinical trials to ascertain safety, efficacy, and long-term impacts, bridging the gap toward precision medicine in microbiome therapies [21].

Next-Generation Probiotics: Focus on Akkermansia muciniphila

Among next-generation probiotics, Akkermansia muciniphila represents a prominent candidate, exhibiting strong inverse associations with obesity, diabetes, and low-grade inflammation. Preclinical studies have causally linked administration of this mucin-degrading bacterium to amelioration of metabolic parameters. Notably, pasteurized forms of A. muciniphila display enhanced efficacy compared to live preparations, potentially due to the stabilization and potency of outer membrane proteins such as Amuc_1100. These advances position A. muciniphila as a promising agent for the development of novel pharmaceuticals or dietary supplements aimed at restoring microbial balance and improving metabolic health. Continued research into molecular mechanisms and clinical translation is critical for harnessing its therapeutic potential [15,22].

Microbiome-Derived Metabolite-Based Therapeutics

Beyond living microbes, microbiome-derived metabolites such as SCFAs, succinate, and microbial catabolites of dietary polyphenols (e.g., hydrocinnamic acid) are emerging as pivotal mediators of host metabolic regulation. These small molecules influence key signaling pathways including AMP-activated protein kinase activation, bile acid receptor modulation, and energy homeostasis.

Identifying and harnessing these metabolites offer potential for adjunct or alternative pharmacological strategies that modulate host metabolism without directly altering microbial communities. Dietary interventions high in polyphenols or specific fiber types can foster beneficial metabolite production, representing an intersection of nutritional and pharmacological approaches. The targeted use of such metabolites or their precursors may refine therapies for obesity and associated metabolic diseases [2,12,23].

Integration of Pharmacological Modulation with Dietary and Lifestyle Interventions

Synergistic Effects of Diet, Pharmacology, and Microbiome

Diet is a primary modulator of gut microbial composition and function, influencing the efficacy of pharmacological microbiome-targeted therapies. High-fiber diets enrich SCFA-producing microbes, enhancing drug-induced metabolic improvements. Caloric restriction combined with psychological interventions can shift microbial diversity and improve psychometric outcomes, indicating multidimensional impacts of diet and lifestyle on gut health.

Integrating diet, psychosocial factors, and pharmacological treatments can potentiate therapeutic effects, underscoring the necessity for holistic intervention strategies in metabolic disorders. These synergies highlight the importance of personalized, multifaceted approaches for sustained microbiome and metabolic benefits [7,24,25].

Role of Prebiotics, Synbiotics, and Phytochemicals

Prebiotics, non-digestible substrates that selectively stimulate beneficial microbial growth, are central to microbiota modulation. Clinical studies combining prebiotics with probiotics (synbiotics) have shown improvements in metabolic markers, inflammation, and gut barrier integrity. Phytochemicals with prebiotic activity, such as iridoid glycosides, have demonstrated potential in remodeling the gut microbiota to favor beneficial taxa like Akkermansia muciniphila.

The interplay of these agents offers promising avenues to complement pharmacological interventions, contributing to more effective and sustainable management of metabolic disorders. Nonetheless, optimization of dosage, duration, and strain specificity remains critical for maximizing therapeutic impact [4,9,22].

Considerations for Personalized Therapy Approaches

Personalization in microbiome-targeted therapies is imperative due to interindividual variability in microbiota composition, host genetics, and environmental exposures. The development of predictive biomarkers to stratify patients based on microbiome profiles can inform tailored treatment regimens.

Emerging strategies incorporate multi-omics integration to refine patient selection and monitor treatment responses. Such precision medicine approaches hold the promise to optimize efficacy while minimizing adverse effects, advancing microbiome-targeted pharmacotherapy beyond generalized interventions into individualized therapeutics [9,21,26].

Impact of Gut Microbiome Modulation on Specific Metabolic Diseases

Obesity and Insulin Resistance

Obesity is characterized by altered gut microbiota compositions that promote increased energy extraction from the diet and influence fat accumulation. Dysbiotic microbiota patterns include reduced microbial diversity, increased Firmicutes to Bacteroidetes ratio, and enrichment of pro-inflammatory taxa. Pharmacological agents that restore microbial balance, enrich SCFA producers, and improve gut barrier integrity have demonstrated efficacy in reducing adiposity and insulin resistance in both animal models and human studies. Metformin exemplifies such agents by modifying microbial communities to improve glucose metabolism and inflammatory status. Collectively, microbiome-targeted interventions contribute to enhanced insulin sensitivity and weight regulation, highlighting the microbiome as a critical therapeutic axis in obesity management [4,10,27].

Type 2 Diabetes Mellitus (T2DM)

T2DM demonstrates characteristic microbiota alterations, including diminished beneficial species and impaired microbial metabolic functions. Therapeutic agents such as metformin and DPP-4i induce remodeling of the gut microbiome, partially restoring functional and compositional imbalances.

Microbial metabolites, notably SCFAs and succinate, participate in mediating glucose homeostasis. Future therapies are likely to focus on integrating microbiota-targeted strategies with traditional antidiabetic drugs to optimize glycemic control and mitigate complications. Robust clinical evidence supports this integrative approach, though further research is essential to standardize and personalize treatments [10,11,28].

Metabolic-Associated Steatotic Liver Disease (MASLD) and NAFLD

MASLD, encompassing nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), is intricately linked to alterations in the gut-liver axis and microbiota dysbiosis. Disrupted intestinal barrier function and microbial metabolite imbalances drive hepatic inflammation, fibrosis, and progression of liver disease.

Pharmacological modulation of gut microbiota, including probiotics, prebiotics, synbiotics, and FMT, have demonstrated benefits in improving liver enzyme levels, reducing endotoxemia, and normalizing lipid metabolism. Emerging agents targeting bile acid signaling pathways further contribute to the therapeutic landscape. Although promising, these strategies require validation through large-scale randomized clinical trials to establish efficacy and optimal regimens in MASLD management [9,22,29].

Molecular and Cellular Mechanisms Underlying Pharmacological Modulation

Microbiota-Host Immune and Inflammatory Interactions

Microbiome-targeted pharmacological interventions modulate immune responses by influencing gut barrier integrity and systemic inflammation. Improved barrier function reduces endotoxin translocation and downstream activation of Toll-like receptors (TLRs), diminishing the production of pro-inflammatory cytokines and mitigating chronic inflammation—a key contributor to metabolic dysfunction.

Drug-induced shifts in microbiota alter the balance between pro- and anti-inflammatory signals, facilitating immune homeostasis. This immunomodulatory effect has been linked to enhanced glucose metabolism and reduced insulin resistance, reinforcing the therapeutic potential of microbiome modulation in inflammatory pathways involved in metabolic diseases [13,30,31].

Mitochondrial Function and Oxidative Stress Regulation

The p66Shc adaptor protein mediates oxidative stress responses and mitochondrial apoptosis, pathways pivotal in metabolic disease progression. Gut microbiota-derived metabolites influence p66Shc activation and mitochondrial function, thereby modulating host redox balance.

Pharmacological agents that modulate the microbiota can indirectly mitigate oxidative stress and mitochondrial dysfunction by altering microbial metabolites and immune signaling cascades. This microbiome-mitochondria interplay represents a novel mechanistic axis for therapeutic intervention in metabolic syndrome and related disorders [31,32].

Microbial Metabolite Signaling in Host Metabolism

Microbial metabolites such as SCFAs and bile acids serve as crucial signaling molecules interacting with host receptors including FXR, TGR5, and aryl hydrocarbon receptor (AhR), orchestrating diverse metabolic functions. Pharmacological manipulation of these metabolites and their pathways can restore metabolic balance by influencing gluconeogenesis, lipogenesis, energy expenditure, and immune responses. Targeting this metabolite signaling pathways offers mechanistically precise approaches to treat metabolic disorders, representing a frontier in microbiome-based therapeutics [14,33].

Safety, Efficacy, and Challenges in Pharmacological Microbiome Modulation

Risks and Limitations of Current Pharmacological Approaches

While fecal microbiota transplantation and probiotics show therapeutic promise, challenges include procedural risks, reproducibility issues, and potential for unintended dysbiosis or pathogen transfer. Long-term safety profiles remain inadequately characterized, particularly concerning antibiotic resistance development and perturbations of indigenous microbiota.

These concerns necessitate cautious advancement of microbiome-targeted therapies, emphasizing stringent clinical evaluation and monitoring to mitigate adverse outcomes [9,19].

Heterogeneity in Clinical Outcomes and Study Designs

Clinical studies of probiotics, FMT, and related interventions exhibit substantial variability attributable to differences in microbial strains, dosages, treatment durations, and host factors such as genetics and environment. This heterogeneity complicates data interpretation and hinders consensus on optimal therapeutic protocols. Standardization of study designs, inclusion criteria, and outcome measures, alongside biomarker development, are critical to improve the reproducibility and comparability of clinical data [8,34].

Future Directions to Enhance Therapeutic Outcomes

Emerging strategies to enhance microbiome-targeted therapy include development of oral encapsulated formulations for easier administration, live microbial agents tailored to individual microbiota, and integration of multi-omics analyses to guide personalized interventions.

Large-scale, long-term randomized controlled trials are essential to establish efficacy, safety, and durability of microbiome modulation in treating metabolic disorders. Collaborative efforts across disciplines will facilitate translation of microbiome science into clinical practice [9,19,21].

Conclusion and Future Perspectives

In summary, pharmacological modulation of the gut microbiome represents a promising frontier in the management of metabolic disorders, offering benefits through alterations in microbial composition, metabolite production, gut barrier integrity, immune regulation, and metabolic signalling. Established agents like metformin illustrate the synergistic potential of integrating microbiome-targeted effects with conventional mechanisms, particularly when combined with dietary and lifestyle interventions. Emerging technologies, including engineered microbial consortia, next-generation probiotics such as *Akkermansia muciniphila*, and microbiome-derived metabolites, herald a shift toward precision and personalized therapeutics. However, significant challenges—such as incomplete understanding of host–microbiome interactions, variability in individual microbiota profiles, and the need for standardized, long-term clinical evidence—must be addressed to

ensure safety, efficacy, and scalability. Continued multidisciplinary research, biomarker-guided patient selection, and robust translational frameworks will be critical to fully harness the therapeutic potential of microbiome pharmacology in combating metabolic diseases.

Reference

1. J. Kinross, A. Darzi, J. K. Nicholson, "Gut microbiome-host interactions in health and disease," BioMed Central, 2011.
2. S. S. Pillai, C. A. Gagnon, C. Foster, A. Ashraf, "Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes," Journal of Clinical Endocrinology and Metabolism, 2024.
3. K. Huang, L. Wu, Y. Yang, "Gut microbiota: An emerging biological diagnostic and treatment approach for gastrointestinal diseases," JGH Open, 2021.
4. S. K. Maurya, J. S. Pandey, A. Mishra, A. Prajapati, R. K. Srivastava, "Pharmacological Modulation of Gut Microbiota in Metabolic Syndrome," None, 2025.
5. K. Dabke, G. Hendrick, S. Devkota, "The gut microbiome and metabolic syndrome," American Society for Clinical Investigation, 2019.
6. N. G. Vallianou, T. Stratigou, G. S. Christodoulatos, A. Dalamaga, "Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives," Springer Science+Business Media, 2019.
7. Y. Gao, W. Li, X. Huang, Y. Lyu, C. Yue, "Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome," Microorganisms, 2024.
8. Horvath, K. ukauskait, O. Hazia, I. Balzs, V. Stadlbauer, "Human gut microbiome: Therapeutic opportunities for metabolic syndromeHype or hope?," Bioscientifica, 2023.
9. G. Fadieienko, O. Gridnyev, S. Gridnyeva, "Prospective directions of treatment of metabolic dysfunction-associated steatotic liver disease. Focus on intestinal microbiota. Review," Modern Gastroenterology, 2024.
10. C. B. Lee, S. U. Chae, S. J. Jo, U. M. Jerng, S. K. Bae, "The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus," Multidisciplinary Digital Publishing Institute, 2021.
11. B. Ezzamouri, D. Rosrio, G. Bidkhori, S. Lee, M. Uhln, S. Shoaie, "Metabolic modelling of the human gut microbiome in type 2 diabetes patients in response to metformin treatment," Nature Portfolio, 2023.
12. X. Liao et al., "Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis," Elsevier BV, 2019.
13. Y. Han et al., "Intestinal Dysbiosis Correlates With Sirolimus-Induced Metabolic Disorders in Mice.," Transplantation, 2020.
14. J. Jiang et al., "Novel Approaches in Glucose and Lipid Metabolism Disorder Therapy: Targeting the Gut MicrobiotaBile Acid Axis," Biology, 2025.
15. P. D. Cani, W. M. D. Vos, "Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila," Frontiers Media, 2017.
16. Q. Zhang et al., "Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats," SAGE Publishing, 2017.
17. J. Mnzker et al., "Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity," Microbiome, 2022.
18. F. Martin et al., "A topdown systems biology view of microbiomemammalian metabolic interactions in a mouse model," Springer Nature, 2007.
19. V. Stadlbauer, "Liver-Gut-Interaction: Role of Microbiome Transplantation in the Future Treatment of Metabolic Disease," Journal of Personalized Medicine, 2023.
20. Shajahan, "The role of gut microbiota in pediatric obesity: Mechanisms and therapeutic potential," World Journal of Advanced Research and Reviews, 2025.
21. T. Mkilima, "Engineering artificial microbial consortia for personalized gut microbiome modulation and disease treatment.," Annals of the New York Academy of Sciences, 2025.
22. C. Xie, Y. Liu, "258-LB: Iridoid Glycoside Modulates Gut Microbiota and Ameliorates Nonalcoholic Fatty Liver DiseaseRelated Metabolic Disorders," Diabetes, 2023.
23. S. Alqudah et al., "Gut microbial conversion of dietary elderberry extract to hydrocinnamic acid improves obesity-associated metabolic disorders," bioRxiv, 2025.
24. V. Dasriya et al., "Modulation of gutmicrobiota through probiotics and dietary interventions to improve host health," Wiley, 2024.
25. L. Bellach, A. Kautzky-Willer, K. Heneis, M. Leutner, A. Kautzky, "The Effects of Caloric Restriction and Clinical Psychological Intervention on the Interplay of Gut Microbial Composition and Stress in Women," Nutrients, 2024.
26. H. Li, J. Wang, L. Hao, G. Huang, "Exploring the Interconnection between Metabolic Dysfunction and Gut Microbiome Dysbiosis in Osteoarthritis: A Narrative Review," Biomedicines, 2024.
27. Yarahmadi, H. Afkhami, A. Javadi, M. Kashfi, "Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review," Diabetology & Metabolic Syndrome, 2024.
28. V. Hartstra, K. E. Bouter, F. Bckhed, M. Nieuwdorp, "Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes," American Diabetes Association, 2014.
29. R. BenedUbieto, F. J. Cubero, Y. A. Nevzorova, "Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)," Landes Bioscience, 2024.
30. Tsay, J. K. Lim, "NASH and the Gut Microbiome: Implications for New Therapies," Lippincott Williams & Wilkins, 2022.
31. C. D. C. Pinaffi-Langley, E. Melia, F. A. Hays, "Exploring the GutMitochondrial Axis: p66Shc Adapter Protein and Its Implications for Metabolic Disorders," International Journal of Molecular Sciences, 2024.
32. F. S. Bersani et al., "Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction.," Military Medicine, 2020.
33. J. Gao et al., "Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism," Frontiers Media, 2018.
34. M. Khan et al., "THE ROLE OF GUT MICROBIOTA MODULATION IN PREVENTING AND MANAGING SYSTEMIC DISEASES: A MULTISPECIALTY META-ANALYSIS OF EMERGING THERAPEUTIC AND DIAGNOSTIC APPROACHES," None, 2024.